Sameer Kotak

1.4k total citations
34 papers, 1.0k citations indexed

About

Sameer Kotak is a scholar working on Rheumatology, Ophthalmology and Hematology. According to data from OpenAlex, Sameer Kotak has authored 34 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Rheumatology, 8 papers in Ophthalmology and 8 papers in Hematology. Recurrent topics in Sameer Kotak's work include Rheumatoid Arthritis Research and Therapies (16 papers), Autoimmune and Inflammatory Disorders Research (8 papers) and Glaucoma and retinal disorders (8 papers). Sameer Kotak is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (16 papers), Autoimmune and Inflammatory Disorders Research (8 papers) and Glaucoma and retinal disorders (8 papers). Sameer Kotak collaborates with scholars based in United States, United Kingdom and Germany. Sameer Kotak's co-authors include Paul P. Lee, Rohit Varma, Ivan Goldberg, Bonnie Vlahos, Jack F. Bukowski, Maxime Dougados, Ron Pedersen, Joachim Sieper, Andrew Koenig and Désirée van der Heijde and has published in prestigious journals such as PLoS ONE, Ophthalmology and Annals of the Rheumatic Diseases.

In The Last Decade

Sameer Kotak

33 papers receiving 998 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sameer Kotak United States	16	458	405	272	256	153	34	1.0k
Meifen Zhang China	17	226 0.5×	480 1.2×	56 0.2×	355 1.4×	34 0.2×	84	1.2k
Niveditha Mohan United States	8	477 1.0×	46 0.1×	48 0.2×	235 0.9×	172 1.1×	15	1.0k
Petra Nilsson Sweden	13	229 0.5×	30 0.1×	67 0.2×	185 0.7×	94 0.6×	34	1.0k
Anuradha Ganesh Oman	19	45 0.1×	347 0.9×	180 0.7×	43 0.2×	66 0.4×	98	948
Heather G. Mack Australia	12	55 0.1×	223 0.6×	90 0.3×	37 0.1×	33 0.2×	81	623
Heidi Crayton United States	8	389 0.8×	41 0.1×	40 0.1×	215 0.8×	199 1.3×	12	1.0k
Moraye B. Bear United States	10	420 0.9×	17 0.0×	70 0.3×	209 0.8×	255 1.7×	16	1.1k
Rafael Cáliz Spain	18	589 1.3×	12 0.0×	211 0.8×	473 1.8×	166 1.1×	60	1.3k
Ryan Webb United States	12	242 0.5×	70 0.2×	20 0.1×	274 1.1×	34 0.2×	14	683
Linda Carli Italy	16	716 1.6×	18 0.0×	153 0.6×	366 1.4×	80 0.5×	48	977

Countries citing papers authored by Sameer Kotak

Since Specialization

Citations

This map shows the geographic impact of Sameer Kotak's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sameer Kotak with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sameer Kotak more than expected).

Fields of papers citing papers by Sameer Kotak

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sameer Kotak. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sameer Kotak. The network helps show where Sameer Kotak may publish in the future.

Co-authorship network of co-authors of Sameer Kotak

This figure shows the co-authorship network connecting the top 25 collaborators of Sameer Kotak. A scholar is included among the top collaborators of Sameer Kotak based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sameer Kotak. Sameer Kotak is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Edwards, Mark J., Pierre‐Michel Llorca, Maurice T. Driessen, et al.. (2025). Clinical practice guidelines for the treatment of tardive dyskinesia in Europe: A descriptive review. European Psychiatry. 68(1). e115–e115.

Correll, Christoph U., José M. Rubio, Leslie Citrome, et al.. (2024). Introducing S.C.O.P.E. : Schizophrenia Clinical Outcome Scenarios and Patient-Provider Engagement An Interactive Digital Platform to Educate on Schizophrenia Care. CNS Spectrums. 29(5). 516–517. 1 indexed citations

Correll, Christoph U., José M. Rubio, Leslie Citrome, et al.. (2024). Introducing S.C.O.P.E.™ (Schizophrenia Clinical Outcome Scenarios and Patient–Provider Engagement), an Interactive Digital Platform to Educate Healthcare Professionals on Schizophrenia Care. Neuropsychiatric Disease and Treatment. Volume 20. 1995–2010. 2 indexed citations

Argoff, Charles E., et al.. (2024). Real-world effectiveness and satisfaction with intravenous eptinezumab treatment in patients with chronic migraine: REVIEW, an observational, multi-site, US-based study. The Journal of Headache and Pain. 25(1). 65–65. 4 indexed citations

Reed, George, David H. Collier, Andrew Koenig, et al.. (2017). Clinical and demographic factors associated with change and maintenance of disease severity in a large registry of patients with rheumatoid arthritis. Arthritis Research & Therapy. 19(1). 81–81. 7 indexed citations

Pavelká, Karel, Nurullah Akkoç, Mustafa Al‐Maini, et al.. (2017). Maintenance of remission with combination etanercept–DMARD therapy versus DMARDs alone in active rheumatoid arthritis: results of an international treat-to-target study conducted in regions with limited biologic access. Rheumatology International. 37(9). 1469–1479. 17 indexed citations

Moots, Robert J., Ricardo Machado Xavier, Chi Chiu Mok, et al.. (2017). The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: Results from a multinational, real-world clinical practice, non-interventional study. PLoS ONE. 12(4). e0175207–e0175207. 111 indexed citations

Guzmán, Renato, Ricardo Machado Xavier, Qi Shen, et al.. (2016). Two-Year Safety and Efficacy Experience in Patients with Methotrexate-Resistant Active Rheumatoid Arthritis Treated with Etanercept and Conventional Disease-Modifying Anti-rheumatic Drugs in the Latin American Region. The Open Rheumatology Journal. 10(1). 13–25. 3 indexed citations

Wiland, Piotr, Jean Dudler, Douglas J. Veale, et al.. (2016). The Effect of Reduced or Withdrawn Etanercept-methotrexate Therapy on Patient-reported Outcomes in Patients with Early Rheumatoid Arthritis. The Journal of Rheumatology. 43(7). 1268–1277. 10 indexed citations

10.

Burgos‐Vargas, Rubén, James Cheng‐Chung Wei, Mahboob U. Rahman, et al.. (2016). The prevalence and clinical characteristics of nonradiographic axial spondyloarthritis among patients with inflammatory back pain in rheumatology practices: a multinational, multicenter study. Arthritis Research & Therapy. 18(1). 132–132. 41 indexed citations

11.

Maksymowych, Walter P., Maxime Dougados, Désirée van der Heijde, et al.. (2015). Clinical and MRI responses to etanercept in early non-radiographic axial spondyloarthritis: 48-week results from the EMBARK study. Annals of the Rheumatic Diseases. 75(7). 1328–1335. 80 indexed citations

12.

Kotak, Sameer, Jack Mardekian, N. Horowicz-Mehler, et al.. (2015). Impact of Etanercept Therapy on Disease Activity and Health-Related Quality of Life in Moderate Rheumatoid Arthritis Patients Population from a National British Observational Cohort. Value in Health. 18(6). 817–823. 7 indexed citations

13.

Guzmán, Renato, Ricardo Machado Xavier, J. Simón, et al.. (2013). Open-Label Observation of Addition of Etanercept Versus a Conventional Disease-Modifying Antirheumatic Drug in Subjects With Active Rheumatoid Arthritis Despite Methotrexate Therapy in the Latin American Region. JCR Journal of Clinical Rheumatology. 20(1). 25–33. 37 indexed citations

14.

Stein, Joshua D., Leslie M. Niziol, David C. Musch, et al.. (2012). Longitudinal Trends in Resource Use in an Incident Cohort of Open-Angle Glaucoma Patients: Resource Use in Open-Angle Glaucoma. American Journal of Ophthalmology. 154(3). 452–459.e2. 19 indexed citations

15.

Kymes, Steven, Paul P. Lee, David C. Musch, et al.. (2012). The Development of a Decision Analytic Model of Changes in Mean Deviation in People with Glaucoma. Ophthalmology. 119(7). 1367–1374. 5 indexed citations

16.

Schwartz, Gail F., et al.. (2011). Incidence of new coding for dry eye and ocular infection in open-angle glaucoma and ocular hypertension patients treated with prostaglandin analogs: Retrospective analysis of three medical/pharmacy claims databases. BMC Ophthalmology. 11(1). 14–14. 10 indexed citations

17.

Kotak, Sameer, et al.. (2011). A multicenter, retrospective chart review study comparing index therapy change rates in open-angle glaucoma or ocular hypertension patients newly treated with latanoprost or travoprost-Z monotherapy. BMC Ophthalmology. 11(1). 13–13. 5 indexed citations

18.

Varma, Rohit, Paul P. Lee, Ivan Goldberg, & Sameer Kotak. (2011). An Assessment of the Health and Economic Burdens of Glaucoma. American Journal of Ophthalmology. 152(4). 515–522. 284 indexed citations

19.

Hahn, Steven R., David S. Friedman, Harry A. Quigley, et al.. (2010). Effect of Patient-Centered Communication Training on Discussion and Detection of Nonadherence in Glaucoma. Ophthalmology. 117(7). 1339–1347.e6. 42 indexed citations

20.

Schwartz, Gail F., Jason Tan, & Sameer Kotak. (2009). Hyperemia-Associated Costs of Medication Changes in Glaucoma Patients Treated Initially With Prostaglandin Analogs. Journal of Ocular Pharmacology and Therapeutics. 25(6). 555–562. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact